| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.75.4.817 |
| P698 | PubMed publication ID | 3103950 |
| P2093 | author name string | E R Passamani | |
| H T Dodge | |||
| J Gore | |||
| F H Sheehan | |||
| E Braunwald | |||
| D O Williams | |||
| P Canner | |||
| P Van Natta | |||
| B Zaret | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| Streptokinase | Q416485 | ||
| thrombolysis | Q1931577 | ||
| phase I clinical trial | Q5452194 | ||
| plasminogen | Q107129060 | ||
| P304 | page(s) | 817-829 | |
| P577 | publication date | 1987-04-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial | |
| P478 | volume | 75 |
| Q73914281 | "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty |
| Q40002380 | A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: the DERIVATION score. |
| Q68046022 | A system approach to intravenous thrombolysis in acute myocardial infarction in community hospitals: the influence of paramedics |
| Q77766373 | ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Ang |
| Q47111055 | ACTION (acute coronary treatment and intervention outcomes network) registry-GWTG (get with the guidelines) risk score predicts long-term mortality in acute myocardial infarction |
| Q77700125 | Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes |
| Q30425798 | Acute insulin resistance in ST-segment elevation myocardial infarction in non-diabetic patients is associated with incomplete myocardial reperfusion and impaired coronary microcirculatory function |
| Q61648664 | Angiographic correlates of lesion relevance and suitability for percutaneous transluminal coronary angioplasty and coronary artery bypass grafting in the bypass angioplasty revascularization investigation study (BARI) |
| Q77761606 | Angiographic methods to assess human coronary angiogenesis |
| Q36812600 | Assessment of reperfusion of the infarct zone after acute myocardial infarction by serial cardiac troponin T measurements in serum |
| Q73662497 | Bifurcation lesions: two stents versus one stent--immediate and follow-up results |
| Q73857173 | Comparative prognostic significance of simultaneous versus independent resolution of ST segment depression relative to ST segment elevation during acute myocardial infarction |
| Q52915123 | Comparison of dobutamine stress echocardiography and exercise stress Thallium-201 SPECT for detection of myocardial ischemia after acute myocardial infarction treated with thrombolysis. |
| Q42131162 | Compromise of beneficial effects of reperfusion on myocardium supplied by vessels with critical residual stenosis |
| Q70040003 | Coronary angioplasty after recombinant tissue-type plasminogen activator in acute myocardial infarction: a report from the Thrombolysis in Myocardial Infarction (TIMI) Trial |
| Q84337251 | Coronary artery perforation by intracoronary guide wires: risk factors and clinical outcomes |
| Q36156568 | Culprit-only versus staged complete revascularization for patients with ST-segment elevation myocardial infarction and Multivessel disease: a retrospective cohort study |
| Q35687099 | Current status of thrombolytic therapy in acute myocardial infarction |
| Q41696643 | Derivation and Validation of Shock Index as a parameter for Predicting Long-term Prognosis in Patients with Acute Coronary Syndrome |
| Q37695160 | Development and course of heart failure after a myocardial infarction in younger and older people. |
| Q39557017 | Drugs used for disorders of coagulation |
| Q71820207 | Early intravenous thrombolysis in acute myocardial infarction: the Jerusalem experience |
| Q35580615 | Early prediction of improvement in ejection fraction after acute myocardial infarction using low dose dobutamine echocardiography |
| Q73257387 | Early treatment with low-dose enalapril after acute myocardial infarction: an equilibrium radionuclide angiographic study. Enalapril despues del Infarto (EDI) Trial Investigators |
| Q74709375 | Effectiveness of rheolytic coronary thrombectomy with the AngioJet catheter |
| Q56945268 | Effects of Thrombolytic Regimen, Early Catheterization, and Predischarge Angiographic Variables on Six-Week Left Ventricular Function |
| Q70743536 | Effects of intravenous SM-9527 (double-chain tissue plasminogen activator) on left ventricular function in the chronic stage of acute myocardial infarction |
| Q46404902 | Effects of nicorandil on cardiac sympathetic nerve activity after reperfusion therapy in patients with first anterior acute myocardial infarction |
| Q42717484 | Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator |
| Q39539827 | Emergency thrombolysis in acute myocardial infarction |
| Q68429082 | Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a |
| Q43518202 | Energy stores and metabolites in chronic reversibly and irreversibly dysfunctional myocardium in humans. |
| Q37913056 | Expanding indications for the use of thrombolytic agents in acute myocardial infarction |
| Q39488446 | Experience with the use of tPA in the treatment of acute myocardial infarction |
| Q44584951 | Factors determining improvement in left ventricular function after reperfusion therapy for acute myocardial infarction: primacy of baseline ejection fraction |
| Q34103716 | Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy |
| Q57243422 | Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST |
| Q44302978 | High level expression of streptokinase in Escherichia coli |
| Q48827756 | Hyperdensity on non-contrast CT immediately after intra-arterial revascularization |
| Q37294658 | In vitro thrombolytic activity of Dhamasa (Fagonia arabica Linn.), Kushta (Saussurea lappa Decne.), and Guduchi (Tinospora cordifolia Thunb.). |
| Q43840694 | Inducible ventricular arrhythmias and patency of infarct-related artery in survivors of acute myocardial infarction. |
| Q37932377 | Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction |
| Q40889632 | Intravenous thrombolytic therapy in myocardial infarction: an analytical review. |
| Q58976215 | Is a strategy of intended incomplete percutaneous transluminal coronary angioplasty revascularization acceptable in nondiabetic patients who are candidates for coronary artery bypass graft surgery? |
| Q40485987 | Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies |
| Q28193948 | Large intracoronary thrombi with good TIMI flow during acute myocardial infarction: four cases of successful aggressive medical management in patients without angiographically detectable coronary atherosclerosis |
| Q41677106 | Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion |
| Q22242896 | Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: |
| Q37956731 | Management of the patient following coronary thrombolysis |
| Q35581714 | Modern risk stratification in coronary heart disease. |
| Q77313283 | Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease |
| Q44889996 | Myocardial contrast echocardiography in the evaluation of viable myocardium after acute myocardial infarction |
| Q73202208 | Nicorandil affords cardioprotection in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty: assessment with thallium-201/iodine-123 BMIPP dual SPECT |
| Q83912509 | Novel application of black-blood echo-planar imaging to the assessment of myocardial infarction |
| Q42240864 | Oxidized Low Density Lipoprotein and High Sensitive C-Reactive Protein in Non-Diabetic, Pre-Diabetic and Diabetic Patients in the Acute Phase of the First Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention |
| Q34843114 | Pathophysiology and management of right heart ischemia |
| Q33611194 | Predictive value of ventricular arrhythmias for patency of the infarct-related coronary artery after thrombolytic therapy |
| Q39452791 | Prognostic value of clinical markers of reperfusion in patients with acute myocardial infarction treated by thrombolytic therapy |
| Q35224551 | Recombinant Streptokinase for the Treatment of Thrombotic Disorders |
| Q50880748 | Reduction in reperfusion injury by blood-free reperfusion after experimental myocardial infarction. |
| Q69274192 | Regional wall motion index for infarct and noninfarct regions after reperfusion in acute myocardial infarction: comparison with global wall motion index |
| Q37930063 | Reperfusion therapy in acute myocardial infarction: present status and controversy |
| Q41693591 | Right heart ischemia: pathophysiology, natural history, and clinical management |
| Q77361734 | Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention |
| Q70363554 | Safety and efficacy of tissue-type plasminogen activator produced by recombinant DNA technology |
| Q36310090 | Serum thioredoxin 1 level has close relation with myocardial damage amount in acute myocardial infarction patients |
| Q33613012 | Streptokinase resistance: when might streptokinase administration be ineffective? |
| Q67808544 | Streptokinase versus Recombinant Tissue-Type Plasminogen Activator |
| Q37113808 | Technetium 99m sestamibi in the assessment of acute myocardial infarction |
| Q33819693 | The Open-Artery Hypothesis: An Overview |
| Q50089457 | The Prognostic Value of Lipoprotein-Associated Phospholipase A2 in the Long-Term Care of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. |
| Q69907830 | The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty |
| Q70654649 | The choice of thrombolytic agents in the emergency department |
| Q74050939 | The impact of right atrial ischemia on inferior myocardial infarction with extension to right ventricle: transesophageal echocardiographic examination |
| Q43037712 | The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. For the CORE investigators (Collaborative Organisation for RheothRx Evaluation). |
| Q33845254 | The role of coronary artery collaterals in the preservation of left ventricular function: a study to address a long-standing controversy |
| Q33617268 | Therapeutic options in treating acute myocardial infarction |
| Q70061474 | Thrombolysis in acute myocardial infarction |
| Q33977213 | Thrombolysis in the air. Air-ambulance paramedics flying to remote communities treat patients before hospitalization |
| Q53015487 | Thrombolysis in thromboembolic diseases. |
| Q35646270 | Thrombolytic therapy for acute myocardial infarction. Lessons to be learned |
| Q35081866 | Thrombolytic therapy: clinical applications |
| Q37178669 | Thrombus burden is associated with clinical outcome after intra-arterial therapy for acute ischemic stroke. |
| Q73286007 | Time as an Adjunctive Agent to Thrombolytic Therapy |
| Q41199394 | Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty: one-year TIMI phase II pilot results. TIMI Investigators |
| Q38236911 | Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent |
Search more.